argenx (NASDAQ:ARGX) Upgraded at Sanford C. Bernstein

argenx (NASDAQ:ARGX) was upgraded by research analysts at Sanford C. Bernstein from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Monday, MarketBeat reports.

Several other research analysts also recently commented on ARGX. Wells Fargo & Company boosted their price objective on shares of argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Piper Sandler boosted their price objective on shares of argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research report on Tuesday, January 7th. Guggenheim boosted their price objective on shares of argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a research report on Monday, March 10th. HC Wainwright boosted their price objective on shares of argenx from $717.00 to $720.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Finally, Robert W. Baird boosted their price objective on shares of argenx from $650.00 to $680.00 and gave the company a “neutral” rating in a research report on Tuesday, March 4th. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, argenx has an average rating of “Moderate Buy” and an average target price of $687.00.

argenx Trading Down 0.5 %

Shares of ARGX stock opened at $611.18 on Monday. The stock has a market cap of $37.14 billion, a P/E ratio of -694.52 and a beta of 0.59. The stock has a 50 day simple moving average of $636.83 and a 200 day simple moving average of $598.22. argenx has a 1 year low of $349.86 and a 1 year high of $678.21.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Analysts forecast that argenx will post 3.13 EPS for the current year.

Institutional Trading of argenx

Institutional investors have recently modified their holdings of the business. GeoWealth Management LLC boosted its position in argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock valued at $31,000 after acquiring an additional 18 shares during the last quarter. Whipplewood Advisors LLC bought a new stake in argenx during the fourth quarter valued at $37,000. Global Retirement Partners LLC boosted its position in argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after acquiring an additional 48 shares during the last quarter. FIL Ltd bought a new stake in argenx during the fourth quarter valued at $38,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in argenx during the fourth quarter valued at $38,000. Institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.